Spruce Biosciences (SPRB) Stock: Buy, Sell, or Hold?
SPRB - Spruce Biosciences, Inc. Common Stock
$53.70
-0.65 (-1.20%)
âŧ
5d:
-6.95%
30d:
+14.09%
90d:
+9.36%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 13, 2026
0d
Get Alerted When SPRB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: SPRB is fairly priced but lacks strong directional signals. At -20.6% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: SPRB is fairly priced but lacks strong directional signals. At -20.6% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$150.04
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$93.16
42.4% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 13.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: SPRB is currently trading at $53.70, which is considered fair relative to its 30-day fair value range of $48.88 to $59.61. From a valuation perspective, the stock is trading at a discount (Forward PE: 6.6) compared to its historical average (13.1). Remarkably, the market is currently pricing in an annual earnings decline of 20.6% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, SPRB is showing sideways momentum. The price is currently testing key support at $53.09. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: SPRB scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $147.88 (+175.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, SPRB is showing sideways momentum. The price is currently testing key support at $53.09. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: SPRB scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $147.88 (+175.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$48.88 -
$59.61
Company Quality Score
39/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
50.0%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 175.4% below Wall St target ($147.88)
- WARNING: Composite score 39/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$48.88 -
$59.61
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$53.09
Resistance Level
$62.98
Current Trend
Sideways
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
6.57
Wall Street Target
$147.88
(+175.4%)
Revenue Growth (YoY)
-75.9%
Valuation Discount vs History
-20.6% cheaper
PE vs Historical
6.6 vs 13.1
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-20.6%
(market-implied from PE analysis)
1-Year Target
$48.33
(-10%)
2-Year Target
$43.50
(-19%)
3-Year Target
$39.15
(-27%)
3-Yr Target (if PE normalizes)
(PE: 7â13)
$78.06
(+45%)
đĄ
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 6.6 to 13.1
Stabilization Target:
$107.08
(+99.4%)
PE Expansion Potential:
+99.4%
Share & Embed Analysis
Last updated: September 13, 2026 7:18 PM ET
Data refreshes hourly during market hours. Next update: 8:18 PM
Data refreshes hourly during market hours. Next update: 8:18 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SPRB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical âĻ |
STRONG BUY
29 analysts |
$91 | 58 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 56 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 45 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 60 BUY |
|
JSPR
Jasper Therapeutics Inc |
STRONG BUY
11 analysts |
$7 | 62 BUY |
